Resident Review Workshop

Thursday, October 17 – 8:00 a.m. – 12:00 p.m.

Sponsored by:
Wedgewood Pharmacy


Dr. Cheryl London

Signal transduction in normal and neoplastic cells

Time: 8:00 am – 9:45 am

Synopsis:  Advances in molecular biology and genetics have provided a much more comprehensive understanding regarding cellular dysfunction in cancer cells, particularly with respect to aberrant cell signaling.  This knowledge has driven that development of small molecule inhibitors designed to target key aspects of signal transduction through direct inhibition of cell signaling molecules, and modulation of gene expression.  Over 80 small molecule inhibitors are now approved to treat a variety of human cancers, and these have had broad impact on patient outcomes associated with breast cancer, lung cancer, and melanoma, among others.  In comparison, a relatively small number of targeted therapies have been evaluated in veterinary medicine, although novel drug more recently, novel drug combinations have been evaluated in some canine cancers.  This review will cover the basic characteristics of normal cell signaling, address how this is co-opted by tumors to drive uncontrolled cell growth, and discuss the current use of small molecule inhibitors in both human and veterinary cancers.

About the Presenter: Dr. London is the Anne Engen and Dusty Professor of Comparative Oncology and Associate Dean for Research and Graduate Education at the Tufts Cummings School of Veterinary Medicine.  She earned her DVM at the Cummings School, completed a Residency in Medical Oncology at the University of Wisconsin-Madison, and received a PhD in Immunology at Harvard University, where she was also a postdoctoral fellow in the Department of Pathology.  She has over 25 years of experience in translational and comparative oncology and drug development and has ongoing collaborations with the Broad Institute, UMass Medical School, Tufts Medical Center, MIT and the Dana Farber Cancer Institute as well as several projects with industry partners.  She currently holds a joint appointment with the Tufts Clinical Translational Science Institute  where she directs the Research Collaboration Team and leads the High Impact Specialized Innovation Program. 

Dr. Mary-Keira Boss

Time: 10:15 am – 12:00 pm

Radiation Oncology/RadioBiology

Synopsis:  This Resident Review session will be focused on Radiation Oncology and Radiobiology. In this session, we will cover the basics of radiation oncology, spanning radiobiology to radiation physics, and how these topics integrate day-to-day into clinical radiation oncology practice. Throughout the session, we will review: neoplastic and normal tissue responses to radiation exposure, with discussion of classification of tissues into acute responding vs. late responding tissues, and how these classifications factor into the concept of a/b ratio and biologically effective dose (BED) calculations and comparisons; the “Rs” of radiobiology (Repair, Repopulation, Redistribution, Reoxygenation, and Radiosensitivity); the various radiation treatment approaches (photon vs. electron vs. proton radiotherapy; manual calculations, 3D-conformal radiotherapy, Intensity modulated radiation therapy (IMRT), Stereotactic (body) radiotherapy (SBRT/SRT), plesiotherapy) and terms associated with radiation planning (GTV, CTV, PTV) and plan evaluation (dose volume histogram; isodose lines vs. dose color wash); characterizing radiation normal tissue toxicity according to VRTOG criteria (acute and late toxicity); and the clinical considerations associated with the use of radiosensitizers.

About the Presenter:  Dr. Boss received her BS in Animal Science from the University of Massachusetts in 2003 and her DVM from North Carolina State University in 2008.  She is a Diplomate of the American College of Veterinary Radiology (Radiation Oncology) and currently works at the Flint Animal Cancer Center as an Associate Professor of Radiation Oncology.